Genetic test helps predict risk of prostate cancer recurrence

by Leslie Lingaas
Genetic test helps predict risk of prostate cancer recurrence

(Medical Xpress)—Prostate cancer ranks as the most common internal malignancy diagnosed in men in the United States, but often does not require extensive treatment.

A study using tissue samples from men who underwent surgical removal of the prostate at UC San Francisco confirmed that a genetic test that measures cell cycle progression (CCP)—an indicator of how rapidly cancer cells are growing and dividing—can be a useful tool for predicting who will have a recurrence of the disease, especially when combined with existing information from laboratory and pathology tests.

The CCP score provides a that eventually might help guide decisions about whether to pursue additional treatment after surgery, such as .

The study, published in the Journal of Clinical Oncology (2013 Apr 10;31(11):1428-34), used the UCSF Database to access tissue samples and medical records from men who had undergone at UCSF and been followed for at least five years after surgery.

A commercial laboratory operated by Myriad Genetics, the company that developed the test, conducted genetic analysis of the to determine a CCP score in 413 patients. The researchers at UCSF then examined how well the CCP score predicted which men had a recurrence of their disease after surgery.

The CCP score was also evaluated with another validated predictive score, the Cancer of the Prostate Risk Assessment post-surgery score (CAPRA-S). The CAPRA-S score is based on preoperative and information gleaned from surgery, including how much the tumor has invaded tissues surrounding the prostate and how aggressive he look when examined under a microscope.

Investigators found that the CAPRA-S and CCP together they were more useful than either alone, and that adding the CCP was especially helpful in men who appeared to have low-risk disease based on the CAPRA-S score alone.

In addition to the 413 patients in the UCSF group, the researchers also looked at the predictive results of the CCP combined with the CAPRA-S in a group of patients previously studied at the Scott and White Clinic in Georgetown, TX, for whom longer-term follow-up was available. The combination of the CCP and CAPRA-S again accurately predicted recurrence in this group.

"One of the big challenges in prostate cancer is knowing when and how aggressively to treat patients," said Matthew R. Cooperberg, MD, MPH, lead author of the study. "Biomarkers such as the CCP can provide valuable data to guide treatment decisions."

The UCSF Urology Department is currently running additional studies with the CCP score, as well as other promising biomarkers and imaging tests, in men who have not undergone surgery or other treatments.

"Our hope is that these tests will help more men with low-risk prostate cancer avoid unnecessary treatment, while ensuring that those with more aggressive cancers do not miss the window of opportunity for cure," said Cooperberg.

add to favorites email to friend print save as pdf

Related Stories

New prostate cancer test improves risk assessment

May 08, 2013

(Medical Xpress)—A new genomic test for prostate cancer can help predict whether men are more likely to harbor an aggressive form of the disease, according to a new UC San Francisco study. The test, which improves risk ...

Gene test may help guide prostate cancer treatment

May 08, 2013

A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.